Year: 2025

SLINGERLANDS, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, announce its participation in two upcoming investor conferences this week in New York, New York, reinforcing its commitment to ongoing engagement with the financial community. Plug executives, Paul Middleton, CFO and Roberto Friedlander, VP of Investor Relations, will participate in one-on-one meetings with institutional investors to discuss the Company’s strategic priorities and long-term growth plans:December 3, 2025: Jefferies Renewables and Clean Energy Conference, NYC December 4, 2025: B Riley AI, Blockchain & Energy Conference, NYCAdditional information on Plug’s investor conference participation can be found in the Investor Resources section of the Company’s...

Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8 Topics Covered by Drs. Leslie Citrome, Marc Milano, and Leon Ravin to Include Opportunities and Advantages of Self-Administered Treatments at Home NEW HAVEN, Conn., Dec. 03, 2025 (GLOBE NEWSWIRE) — As millions of patients and caregivers continue to struggle with acute agitation episodes associated with bipolar disorder and schizophrenia, a timely and highly anticipated virtual roundtable will bring together leading medical experts to discuss the future of care, including the growing potential for safe, effective self-administered treatments at home. Hosted by Anjalee Khemlani, an award-winning healthcare journalist known for her in-depth reporting at Yahoo Finance and NJBIZ, the one-hour event will take place Monday, Dec. 8, at 10 a.m. EST. Pre-registration...

Advances electrification of calcination furnaces in the cement industry using plasma torch technology MONTREAL, Dec. 03, 2025 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), the leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces that it has signed a EUR815,000 (CAD$1,324,000) contract with a European cement industry customer for the supply of a plasma torch system for the electrification of a calcination furnace. The client’s name is being withheld for competitive and confidentiality reasons. This contract was originally noted in the Outlook section of PyroGenesis’ second quarter financial results (press release dated August 6, 2025). PROJECT HIGHLIGHTS Purpose: using an electric plasma...

Heineken 0.0 Zero JudgementA Media Snippet accompanying this announcement is available by clicking on this link. AMSTERDAM, Dec. 03, 2025 (GLOBE NEWSWIRE) — The World has finally called time on ‘drinking pressure’ as society moves to a place where the uncomfortable question of ‘’why aren’t you drinking?’’ is officially more awkward to ask than answer. A new global study* from Heineken® 0.0, the World’s number 1† non-alcoholic beer, reveals that 2025 marks the first festive season where saying “no thanks” needs no excuse, with almost three-quarters (72%) of people confident to skip alcohol without fear of being judged or excluded. Attitudes towards drinking alcohol are changing fast. The study, carried out in five countries* in partnership with renowned author of Sober Curious, Ruby Warrington, reveals over two-thirds (67%) of...

Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03 and p=0.04, respectively) Statistical significance was achieved in all type 1 error controlled secondary endpoints Results demonstrate clinically meaningful and statistically significant skeletal and cardiac benefits, supporting Deramiocel as a potential first-in-class therapy designed to treat Duchenne cardiomyopathy, the leading cause of mortality in Duchenne Deramiocel maintained a favorable safety and tolerability profile consistent with prior clinical experience Company plans to submit its response to the Complete Response Letter incorporating HOPE-3 data, following prior alignment with FDA Conference call and webcast today at...

Advertisement THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM CANADA, SWITZERLAND OR INDIA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL. Amsterdam, The Netherlands 3 December 2025 The Magnum Ice Cream Company Announces Publication of Prospectus The Magnum Ice Cream Company N.V. (“TMICC”) confirms that its prospectus in relation to the admission of TMICC’s ordinary shares to: (i) listing and trading on Euronext Amsterdam (the “Amsterdam Admission”); and (ii) listing on the Equity Shares (Commercial Companies) category of the Official List of the UK Financial Conduct Authority (“FCA”) and trading on the London Stock Exchange’s main market for listed securities (the “London Admission” and together with the Amsterdam Admission, “Admission”)...

Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals observed to date PFS data for 1L NSCLC patients expected in Q2 2026; Company continues to explore partnership opportunities for pivotal development of silevertinib Based on encouraging CNS activity of silevertinib in multiple trials across NSCLC and GBM, Company plans to initiate a randomized Phase 2 trial of silevertinib in newly diagnosed GBM patients in 1H 2026; initial data anticipated in 2028 Cash, cash equivalents, and investments of $135.5 million as of September 30, 2025; expected to be sufficient to fund operations into 2H of 2028 Company to host an investor webcast and conference call today at 8:00 AM ETCAMBRIDGE,...